Ayvakit
Blueprint’s latest approval for Ayvakit sets up clash with Novartis
Phil Taylor
Ayvakit, Blueprint Medicines, FDA approval, Novartis, Oncology, Rydapt, systemic mastocytosis
0 Comment
X
Blueprint’s latest approval for Ayvakit sets up clash with Novartis
https://pharmaphorum.com/news/blueprints-latest-approval-for-ayvakit-sets-up-clash-with-novartis/
Market Access/ News/ News/ News/ Oncology
Blueprint pays the price of Ayvakit phase 3 miss as FDA rejects drug
Phil Taylor
Ayvakit, Blueprint Medicines, Deciphera, Oncology, Qinlock, stomach cancer
0 Comment
X
Blueprint pays the price of Ayvakit phase 3 miss as FDA rejects drug
https://pharmaphorum.com/news/blueprint-pays-the-price-of-ayvakits-phase-3-miss-as-fda-rejects-drug/